Nello Mainolfi, Kymera CEO
Kymera and Sanofi move ahead with skin drug after promising PhI data
Kymera and Sanofi plan to move ahead with the skin drug that the French drugmaker paid $150 million in cash in 2020 to partner on …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
